Benign prostatic hyperplasia

An in-depth report about the causes, diagnosis, treatment, and prevention of benign prostatic hyperplasia (BPH).

I Would Like to Learn About:

Related Reports

Prostate cancer

References

Andersson KE, Wein AJ. Pharmacologic management of lower urinary tract storage and emptying failure. In: Partin AW, Dmochowski RR, Kavoussi LR, Peters CA, eds. Campbell-Walsh-Wein Urology. 12th ed. Philadelphia, PA: Elsevier; 2021: chap. 120.

Capogrosso P, Salonia A, Montorsi F. Evaluation and nonsurgical management of benign prostatic hyperplasia. In: Partin AW, Dmochowski RR, Kavoussi LR, Peters CA, eds. Campbell-Walsh-Wein Urology. 12th ed. Philadelphia, PA: Elsevier; 2021: chap. 145.

Foster HE, Barry MJ, Dahm P, et al. Surgical management of lower urinary tract symptoms attributed to benign prostatic hyperplasia: AUA Guideline. J Urol. 2018;200(3):612-619. PMID: 29775639 pubmed.ncbi.nlm.nih.gov/29775639/.

Helo S, Welliver RC, McVary KT. Minimally invasive and endoscopic management of benign prostatic hyperplasia. In: Partin AW, Dmochowski RR, Kavoussi LR, Peters CA, eds. Campbell-Walsh-Wein Urology. 12th ed. Philadelphia, PA: Elsevier; 2021: chap. 146.

Jones P, Rai BP, Nair R, Somani BK. Current status of prostate artery embolization for lower urinary tract symptoms: review of world literature. Urology. 2015;86(4):676-681. PMID: 26238328 pubmed.ncbi.nlm.nih.gov/26238328/.

Kaplan SA. Benign prostatic hyperplasia and prostatitis. In: Goldman L, Schafer AI, eds. Goldman-Cecil Medicine. 26th ed. Philadelphia, PA: Elsevier Saunders; 2020:chap 120.

Kim EH, Larson JA, Andriole GL. Management of benign prostatic hyperplasia. Annu Rev Med. 2016;67:137-151. PMID: 26331999 pubmed.ncbi.nlm.nih.gov/26331999/.

Langan RC. Benign Prostatic Hyperplasia. Prim Care. 2019;46(2):223-232. PMID: 31030823 pubmed.ncbi.nlm.nih.gov/31030823/.

Madersbacher S, Roehrborn CG, Oelke M. The role of novel minimally invasive treatments for lower urinary tract symptoms associated with benign prostatic hyperplasia. BJU Int. 2020;126(3):317-326. PMID: 32599656 pubmed.ncbi.nlm.nih.gov/32599656/.

McVary KT, Roehrborn CG, Avins AL, et al. Update on AUA guideline on the management of benign prostatic hyperplasia. J Urol. 2011;185(5):1793-1803. PMID: 21420124 pubmed.ncbi.nlm.nih.gov/21420124/.

Mock S, Dmochowski R. Benign prostatic hyperplasia and related entities. In: Hanno PM, Guzzo TJ, Malkowicz SB, Wein AJ, eds. Penn Clinical Manual of Urology. 2nd ed. Philadelphia, PA: Elsevier Saunders; 2014:chap 15.

Parsons JK, Dahm P, Köhler TS, Lerner LB, Wilt TJ. Surgical management of lower urinary tract symptoms attributed to benign prostatic hyperplasia: AUA guideline amendment 2020. J Urol. 2020;204(4):799-804. PMID: 32698710 pubmed.ncbi.nlm.nih.gov/32698710/.

Pattanaik S, Mavuduru RS, Panda A, et al. Phosphodiesterase inhibitors for lower urinary tract symptoms consistent with benign prostatic hyperplasia. Cochrane Database Syst Rev. 2018;11:CD010060. PMID: 30480763 pubmed.ncbi.nlm.nih.gov/30480763/.

Powell T, Kellner D, Ayyagari R. Benign prostatic hyperplasia: clinical manifestations, imaging, and patient selection for prostate artery embolization. Tech Vasc Interv Radiol. 2020;23(3):100688PMID: 33308530 pubmed.ncbi.nlm.nih.gov/33308530/.

Roehrborn CG, Strand DW. Benign prostatic hyperplasia: etiology, pathophysiology, epidemiology, and natural history. In: Partin AW, Dmochowski RR, Kavoussi LR, Peters CA, eds. Campbell-Walsh-Wein Urology. 12th ed. Philadelphia, PA: Elsevier; 2021: chap. 144.

US Preventive Services Task Force, Grossman DC, Curry SJ, Owens DK, et al. Screening for prostate cancer: US Preventive Services Task Force recommendation statement. JAMA. 2018;319(18):1901-1913. PMID: 29801017 pubmed.ncbi.nlm.nih.gov/29801017/.

BACK TO TOP

Review Date: 5/29/2021  

Reviewed By: Kelly L. Stratton, MD, FACS, Associate Professor, Department of Urology, University of Oklahoma Health Sciences Center, Oklahoma City, OK. Also reviewed by David Zieve, MD, MHA, Medical Director, Brenda Conaway, Editorial Director, and the A.D.A.M. Editorial team.

ADAM Quality Logo
Health Content Provider
06/01/2025

A.D.A.M., Inc. is accredited by URAC, for Health Content Provider (www.urac.org). URAC's accreditation program is an independent audit to verify that A.D.A.M. follows rigorous standards of quality and accountability. A.D.A.M. is among the first to achieve this important distinction for online health information and services. Learn more about A.D.A.M.'s editorial policy, editorial process and privacy policy. A.D.A.M. is also a founding member of Hi-Ethics. This site complies with the HONcode standard for trustworthy health information: verify here.

The information provided herein should not be used during any medical emergency or for the diagnosis or treatment of any medical condition. A licensed medical professional should be consulted for diagnosis and treatment of any and all medical conditions. Links to other sites are provided for information only -- they do not constitute endorsements of those other sites. © 1997- 2022 A.D.A.M., a business unit of Ebix, Inc. Any duplication or distribution of the information contained herein is strictly prohibited.

A.D.A.M. content is best viewed in IE9 or above, Firefox and Google Chrome browser.